在扩散阶段小细胞肺癌中使用杜尔瓦卢马布加乙:来自Caspian第三阶段研究的年龄,性别和子组的结果

Niels Reinmuth1, Jonathan W Goldman2, Yuanbin Chen3

  • 1Asklepios Lung Clinic, Member of the German Center for Lung Research (DZL), Munich-Gauting, Germany.

Clinical lung cancer
|August 31, 2025
PubMed
概括

第一线杜尔瓦卢马布加上埃托波和化疗改善了扩散阶段小细胞肺癌患者的整体存活率. 疗效在各个小组中一致,对患者报告的结果没有负面影响.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K